Porton Biopharma, is working together with Public Health England and US company NanoBio Inc. to develop a next generation anthrax vaccine at PBL’s facilities in Porton, Wiltshire, UK. This programme is currently funded by the US Government, through its National Institute of Allergy and Infectious Diseases (NIAID). The total value of the contract (number HHSN272201600045C) could be worth up to £14million (US $24million) over its 8 year term, if all options are exercised.
If successful the next generation vaccine will combine the PBL’s expertise with anthrax vaccine antigens and US Company NanoBio Inc’s stabilisation technology enabling immunity to be achieved by fewer doses than current vaccines and by intra-nasal spray device instead of an injection.
Porton Biopharma Ltd (PBL) announced in June 2017 that it had signed a modification to its contract to cover the next phase of the programme. The contract modification is worth US$5.6 million.
PBL’s contract supports the advanced development of candidate vaccine components and technologies that accelerate the immune responses for use in post-event settings following the intentional release of the Category A priority pathogen Bacillus anthracis, the bacterium that causes the disease anthrax, or in response to naturally occurring outbreaks of the disease.
Commenting on the award, Dr Roger Hinton Managing Director of PBL said “NIAID’s approval to progress funding of the contract is testament to the tremendous amount of hard work and dedication that has gone into the development of this novel product to date by PBL and its partners in collaboration with NIAID’s technical team. It both recognises the knowledge and expertise of our staff and demonstrates the ability of PBL as a young and growing company to deliver. This programme is a continuation of our track record of developing and manufacturing life-saving and protecting products many of which are sold in worldwide markets which includes the UK anthrax vaccine.